It was evident that patients in the LN active group had higher serum levels of CXCL9 (Figure 4A, 120.37 ± 32.65 pg/mL in LN inactive vs. 145.72 ± 30.68 pg/mL in LN active, p = .003), CXCL10 (Figure 4B, 118.61 ± 30.87 pg/mL in LN inactive vs. 137.04 ± 26.34 pg/mL in LN active, p = .013), and CXCL11 (Figure 4C, 86.59 ± 22.04 pg/mL in LN inactive vs. 107.86 ± 28.57 pg/mL in LN active, p = .004), indicating a correlation between the serum levels of CXCL9, CXCL10, and CXCL11 and the activity level of LN in SLE patients with concurrent LN. Here, CXCL9 is linked to lobular neoplasia.